Cri­net­ics re­ports sec­ond PhI­II win for acromegaly drug, eyes 2025 launch

Cri­net­ics’ sec­ond Phase III tri­al in­ves­ti­gat­ing its drug pal­tuso­tine in a rare hor­mon­al dis­or­der read out topline da­ta on Tues­day, with the drug notch­ing an­oth­er win by hit­ting its pri­ma­ry and sec­ondary end­points.

In the PATHFN­DR-2 study, Cri­net­ics stud­ied its oral, once-dai­ly drug in 111 par­tic­i­pants with acromegaly who were not phar­ma­co­log­i­cal­ly treat­ed. For the pri­ma­ry end­point, 56% of pa­tients achieved an in­sulin-like growth fac­tor 1 (IGF-1) lev­el less than or equal to 1.0 times the up­per lim­it of nor­mal com­pared to 5% on place­bo, earn­ing a p-val­ue of p<0.0001.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER